AstraZeneca makes a narrow escape from UK Seroquel probe
This article was originally published in Scrip
Executive Summary
AstraZeneca's blockbuster atypical antipsychotic Seroquel (quetiapine) has been in the news quite a bit these days in relation to the multi-million-dollar settlements of its off-label probes in the US. This week, the UK's self-regulatory body for the industry, the PMCPA, published the outcome of a case on Seroquel. Although AstraZeneca escaped any sanctions by the skin of its teeth, the case raises a number of important questions for UK industry self-regulation.